Case Study: Merck & Co., Inc.

Those target markets who rely on Johnson & Johnson health and medical needs are mostly patients, doctors, nurses and civilians. Therefore, the company need to sustain their products and services over all these years to ensure that lower income people and underprivileged patients are able to access on their medicines. This however requires the company to balance patient’s access and competitive dynamics in line with their need as the company need to have enough resources to keep on being innovating, creating new and better medicines and at the same time making sure there will be a fair return to the shareholder as well. Johnson & Johnson also work closely with the governments, physicians, non-government organizations and the international donors all around the world to provide its products within an affordable prices to its

CVS's retail pharmacy operations are functioning poorly and dissatisfying customers. Many customers are defecting as a result. A pharmacy service improvement team has documented the current prescription fulfillment process, its exception rates, and the problems generated by exceptions. The company must now decide how to change this process, and what information system changes to make in support of the redesigned process.

Pfizer is the largest American pharmaceutical company and one of the largest pharmaceutical companies in the world. It competes with Merck and Glaxo, and markets such well-known medications as Celebrex and Viagra. However, the pharmaceutical industry as a whole has undergone changes in recent years with significant consolidation taking place and with increased scrutiny regarding the ways in which drugs are developed, tested and marketed. In addition, recent controversies have erupted regarding Merck's drug Vioxx, and Pfizer has been the target of unwanted publicity regarding its painkiller Celebrex. This research considers the strategic position of Pfizer, including its strengths and weaknesses as well

However, he took his turn point in his career when he accepted the position as general counsel at Merck & Co. Inc pharmaceutical company in 1992. During the time he serve as general counsel, he create a great success by leading the company through more than 5000 lawsuit that cause by the harmful side effects of Vioxx (Rofecoxib). And by judging his excellent performance and well understanding on the cooperate management, he was offer a position in the management team of the company. At 2007, he was elected as the president of Merck & Co. Inc. Lately on 2015; he was elected to be new chairman of PhRMA.

Johnson and Johnson’s is a multi-billion dollar company that has been around for 129 years. The company was founded in 1886 by Robert Wood Johnson joined his brothers James Wood Johnson and Edward Mead Johnson to create a line of ready-to-use surgical dressings in 1885. The company produced its first products in 1886 and incorporated in 1887 (Johnson).Since then the company has built a reputation on its “Credo”. Simply stated, the first responsibility is to the doctors, nurses, patients, mothers and fathers who use the products then, employees, and finally shareholders. This lines up with the humanistic view of putting people over profits. As Johnson and Johnson’s grew, the company moved form a simple structure, offering just ready to use surgical dressings into a divisionalized form of many departments. With a host of products from band aids to high-margin medical devices: artificial hips and knees, heart stents, surgical tools and monitoring devices; and from still higher-margin prescription drugs targeting Crohn’s disease, cancer , schizophrenia , diabetes , psoriasis , migraines , heart disease and attention deficit disorder (Brill).This decentralized organization structure of management offered autonomy to mid and lower level manager . The issues that arose as the company grew under the structural from where Did Johnson and Johnson’s hide Risperdal study results from the Food and Drug Administration (FDA). Moreover, was there illegal marking of Risperdal?

The Medco acquisition was the consequence of a study initiated in 1992 by Merck to examine the role of pharmaceuticals in the larger context of health care. Merck realized that drug companies had to view themselves as health care solution providers rather than as suppliers of medicines. Merck also realized that drugs were becoming commodities due to generics and HMOs. Merck felt that the acquisition of a PBM would provide access to key players in the health care industry such as physicians, employers, pharmacists and patients. The huge amounts of drug

I will be evaluation my current job at the pharmacy. It is a functioning retain pharmacy that’s main purpose is to distribute drugs and assist in the wellbeing of our community.

Merck is facing patent expiration problem because most of its popular drugs are going to expire by 2002. Patent expiration will lead to a substantial loss of sales. Therefore, Merck must develop new compounds quickly to refresh its portfolio and counter the loss of sales.

Do you believe that Merck acted in a socially responsible and ethical manner with regard to Vioxx? Why or why not? (In your answer, please address the company’s drug development and

Research and Development: Merck is a research-driven company that has a new research and development model incorporating its business strategy. Merck hopes to improve the success of is R&D and to reduce costs by focusing on therapeutic areas that have unmet medical needs, and scientific and commercial opportunity. It plans to develop products within these therapeutic areas that are highly valued by patients and doctors.

Since its humble beginning as a small drugstore, Merck has placed a large amount of importance on improving the health and well-being of its customers. As drug patents expire and genetic forms of their top products become available, Merck’s strategy is to do the unexpected; instead of raising the price of their older products in favor of patent protected new drugs, Merck focuses on reducing their cost in order to better compete with their generic counterparts. Additionally, Merck’s plan for growth now encompasses a much more aggressive pursuit of new drugs in their pipeline through extensive research. Merck became the second largest health care company in the world after the merger with Schering-Plough in 2009 and has

In the last several years, Merck’s individual R &D department has not been able to keep pace with declining revenues from existing products. It is only through Mergers and Acquisitions that Merck has supplemented this income.

In summary of the Pfizer case study, the organization realized executives and key employees were spending 20-40% of their time on support work rather than knowledge work. In response, the company started a “magic button” process. When an employee would like to pass off the tasks that are monotonous or lack luster they can press the “magic button”. The tasks are assigned to individuals of an outside organization for completion. The result is an increase of employee productivity.

Unlike Gilead that has only one product in its Oncology line, Bristol-Myers Squibb presently have four different drugs namely: Erbitux –an epidermal growth factor receptor (EGFR) antagonist for the treatment of Head & Neck cancer and Colorectal cancer,(2) Opdivo (nivolumab) for the treatment of unresectable or metastic melanoma and lungs cancer, (3) Syrcel( dasatinb) for the treatment of newly diagnosed adult with Philadelphia chromosome –positive (ph+) chronic myeloid leukemia and (4) Yervoy (ipilimumob) for the treatment of melanoma a type of skin cancer that spread and as such cannot be remove by surgery. Like Seattle Genetics, the company products use either Antibody-drug Conjugate (ADC) though in a different version by linking potent cytotoxic to monoclonal antibodies targeted to specific tumor cells or immune-oncology, an innovative technology that unlocks the body own immune system to fight against cancerous cells. It also expanded its focus to Nolch inhibitor (used in blocking powerful pathway that promotes tumor cell survival for certain other types of cancer. (Bristol-Myer Squibb, 2014) Because the technology is similar but used differently, BMS would be considered a close competitor who currently has the advantage of having four targeted specific drugs and 12 other oncology and immune-oncology in various trial phases.

The Bayer Corporation was founded in Friedrich Bayer in 1863. The company’s first product was aspirin and it was widely successful and is still sold today. Their next major drug the company produced was diacetylmorphine, also known as heroin. Bayer trademarked the name ”heroin” and sold the drug as a cough suppressant and non-addictive alternative to morphine in the early 1900s. Now the company is a multinational, pharmaceutical and life sciences company based out of Leverkusen, Germany. They handle a very wide berth of markets and so the company is structured in divisions. These divisions include Pharmaceuticals, Consumer Health, Crop Science, Animal Health. Pertaining to healthcare the company creates a variety of products, some of the